This commentary suggests that the FDA should err on patients’ right to choose rather than erring on the side of safety

This commentary suggests that the FDA should err on patients’ right to choose rather than erring on the side of safety

“The notion FDA should “err on the side of safety” must be qualified for patients with incurable or poorly treatable diseases: For them, there is no safety in the status quo, and they are only damaged further by paternalistic public policies that prevent them from exercising their own judgment about risks and benefits. If FDA must err, it should be on the side of patients’ freedom to choose.”